THOUSAND OAKS, Calif., Feb. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases (spread of cancer to the bone) at today’s meeting of the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC).
Read the rest of this entrySOURCE